TrovaGene, Inc.

11055 Flintkote Avenue
San Diego
California
92121
United States

Tel: 858-952-7570

Show jobs for this employer

About TrovaGene, Inc.

We are a clinical stage precision medicine biotechnology company developing oncology therapeutics for hematologic and solid tumor cancers. Beginning with our lead drug candidate PCM-075, a Polo-like Kinase 1 (PLK1) Inhibitor, we are on a journey to develop new treatment options to help transform cancer care.

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. Now with the FDA’s granting of orphan drug designation for PCM-075 to treat patients with Acute Myeloid Leukemia (AML), and initiation of our Phase 1b/2 clinical trial, we are moving forward with our clinical development program.

We optimize drug development by leveraging our significant experience and expertise in biomarker and Precision Cancer Medicine® (PCM) technology to address the need for new therapeutic options to treat hematologic and solid tumor cancers.

Stock Symbol: TROV

Stock Exchange: NASDAQ

256 articles with TrovaGene, Inc.